Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study on the Burden of Influenza-related Hospitalizations and Emergency Room (ER) Visits in Children in Spain

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: May 3, 2012
Last updated: NA
Last verified: May 2012
History: No changes posted
This study aims to quantify the inpatient and ER visits burden of laboratory-confirmed influenza, and compare the clinical features, severity, complications, risk factors and socioeconomic impact of influenza in children presenting with acute respiratory illness (ARI) and/or isolated fever, with or without laboratory-confirmed influenza.

Condition Intervention
Procedure: Throat swab and/or nasopharyngeal swab
Other: Data collection

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Burden of Influenza-related Hospitalizations and ER Visits in Children in Spain

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Laboratory-confirmed influenza in children presenting with ARI and/or isolated fever [ Time Frame: Day 0 till Day 28-37 ]
  • Direct medical cost per hospitalization or ER visit with laboratory-confirmed influenza [ Time Frame: Day 0 till Day 28-37 ]

Secondary Outcome Measures:
  • Laboratory-confirmed respiratory viruses in children presenting with ARI and/or isolated fever [ Time Frame: Day 0 till Day 28-37 ]
  • Occurrence of death [ Time Frame: Day 0 till Day 28-37 ]
  • Occurrence of secondary bacterial infections [ Time Frame: Day 0 till Day 28-37 ]
  • Potential risk factors [ Time Frame: Day 0 till Day 28-37 ]
  • Number of days of hospitalization [ Time Frame: Day 0 till Day 28-37 (between October 2010 until May 2011) ]
  • Use of medication [ Time Frame: Day 0 till Day 28-37 ]
  • Number of days of school absenteeism [ Time Frame: Day 0 till Day 28-37 ]
  • Number of days of parent or caregiver time off work [ Time Frame: Day 0 till Day 28-37 ]
  • Number of household members with influenza-like illness [ Time Frame: Day 0 till Day 28-37 ]

Enrollment: 501
Study Start Date: November 2010
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Influenza Group
Children <15 years of age hospitalized for or presenting to an ER for acute ARI and/or isolated fever during the influenza season.
Procedure: Throat swab and/or nasopharyngeal swab
Samples will be tested to quantify the inpatient and ER visits burden of laboratory-confirmed influenza.
Other: Data collection
Log Sheet will be used to collected data on a monthly basis for the following age groups: < 6 months; 6-23 months; 24-59 months; > 5 years.

Detailed Description:

The total medical cost associated with each hospitalization or ER visit will also be calculated at the end of this study.

The study will be conducted from October, 2010, until May, 2011. Each subject will be followed-up for 21-30 days via telephone. The follow-up medical chart review will preferably be performed within 7 days after the telephone contact.


Ages Eligible for Study:   up to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects for whom the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol.
  • A male or female <15 years of age at the time of study entry. A subject will become ineligible on his/her 15th birthday.
  • Signed informed consent from the parents or guardians of the subject and signed assent from children ≥ 12 years old.
  • Presenting with a sudden onset clinical process comprising :

    • Isolated fever defined as: oral temperature ≥ 37.5°C / axillary temperature ≥ 37.5°C / Rectal temperature ≥ 38°C / tympanic temperature on oral setting ≥ 37.5°C / tympanic temperature on rectal setting ≥ 38°C without an obvious cause.


  • ARI defined as one or more of the following symptoms: sore throat, coryza, cough, breathing difficulties.

Exclusion Criteria:

• Children in foster care.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01592799

GSK Investigational Site
Bilbao, Spain, 48013
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT01592799     History of Changes
Other Study ID Numbers: 114004
Study First Received: May 3, 2012
Last Updated: May 3, 2012

Keywords provided by GlaxoSmithKline:

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases processed this record on April 28, 2017